Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis

  • Amy Paller (Creator)
  • E. Siegfried (Creator)
  • M. Cork (Creator)
  • A. Wollenberg (Creator)
  • Peter D. Arkwright (Contributor)
  • Mercedes Gonzalez (Creator)
  • Benjamin Lockshin (Creator)
  • Zhen Chen (Creator)
  • Ashish Bansal (Creator)
  • Noah A. Levit (Creator)
  • Randy Prescilla (Creator)
  • Elaine C Siegfried (Creator)
  • Michael J. Cork (Creator)
  • Andreas Wollenberg (Creator)
  • Randy Prescilla (Creator)



The above Video Abstract, Key Points and Plain Language Summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2022
Date made available2023
PublisherAdis Journals

Cite this